# Stopping as a Clinical Transition

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/stopping-as-a-clinical-transition

> A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.

## Key points

- HbA1c returns to baseline within 12–18 months of stopping.
- Two reviews disagree on whether outcome data after stopping exists. Both are defensible.
- Regain is named as biology: orexigenic reactivation plus adaptive thermogenesis.
- 'No validated tapering strategies': nobody has established how to stop safely.

A review argues that coming off these drugs should be treated as a **high-risk clinical transition rather than a treatment endpoint**.[1] It also reports something a review we covered recently said did not yet exist: an association between early discontinuation and later cardiovascular disease. Both statements are defensible, and the gap between them says something about the evidence.

## What the review reports

- **HbA1c normalizes within 12 to 18 months** of stopping, meaning it returns to where it was, which is why [a normal HbA1c on the drug is not remission](https://glpwatchdog.org/research/normal-blood-sugar-is-not-remission).
- **Discontinuation before one year** is associated with increased risks of coronary artery disease and heart failure, compared with continuing.
- **Weight recurrence is biological**: reactivation of orexigenic pathways and adaptive thermogenesis.
- **No validated tapering strategies exist.** Nobody has established how to stop safely.

## The disagreement worth naming

In [the cardiovascular cost of stopping](https://glpwatchdog.org/research/the-cardiovascular-cost-of-stopping), we covered a Nature Reviews Endocrinology review that made the cardiovascular argument carefully and then said plainly that *few data are available regarding the incidence of hard outcomes in people discontinuing such drugs*.

> One review says the outcome data barely exist. The other reports what they show. Both can be right.

The reconciliation is not complicated: an association can exist in observational records while still being thin, unadjusted for the reasons people stop, and far short of what anyone would want before advising a patient. A review emphasizing the absence of good evidence and a review reporting the available evidence are describing the same weak literature from two directions.

The practical consequence is that **the cardiovascular risk of stopping is a real hypothesis with weak support**, and anyone presenting it as established, in either direction, is going beyond what exists.

> **There is an obvious confound in that association, and it points the wrong way for causal claims.** People who stop within a year are disproportionately people who could not tolerate the drug, could not afford it, or became unwell. Every one of those independently predicts worse cardiovascular outcomes. Comparing early stoppers with continuers measures who stops as much as it measures stopping. A trial in which treatment ends on a schedule avoids that. In one, [an intragastric balloon came out on a date set in advance](https://glpwatchdog.org/research/the-day-the-balloon-comes-out), so the regain that followed could not be blamed on who chose to stop.

## The mechanism is the useful part

Where this review adds something our earlier coverage lacked is in explaining *why* weight returns. Two processes are named. One is reactivation of orexigenic pathways: the signaling that drives hunger, suppressed while on the drug and released when it stops. The other is adaptive thermogenesis, the reduction in energy expenditure that follows weight loss and persists.

That framing matters because of what it displaces. Weight returning after stopping is routinely read, including by patients about themselves, as a failure of discipline. Described as orexigenic reactivation against a lowered metabolic rate, it is a physiological response to an intervention being withdrawn, which is what the trial evidence has consistently shown.

## What to do with 'no validated tapering strategies'

That phrase is the center of the review. There is no evidence-based way to come off these drugs. The authors suggest structured multidisciplinary transitions combining pharmacological, behavioral and psychological support as the best available approach, and say explicitly that they do so in the absence of validated alternatives.

The options with randomized support are ways of not stopping. Reducing to a lower labeled dose held much of the loss while tripling the need for rescue therapy, and a pill maintained 79.3% of the reduction against 37.6% on placebo (see [the maintenance trial](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial) and [the oral handover](https://glpwatchdog.org/research/a-pill-to-hold-what-the-injection-lost)). Neither is a taper; both are alternatives to a full stop. What an abrupt stop from tirzepatide looked like in its withdrawal trial is in [stopping tirzepatide cold turkey](https://glpwatchdog.org/research/stopping-tirzepatide-weight-regain).

And in ordinary care, the average person who stopped regained very little in a year, because most did something else afterward (see [what people actually do after stopping](https://glpwatchdog.org/research/what-people-actually-do-after-stopping)). The catastrophic framing is not supported; the “treat it as a transition” framing is.

## Frequently asked questions

### Is stopping a GLP-1 risky for your heart?

It is an open question with weak support. One review reports early discontinuation associated with more coronary artery disease and heart failure than continuing; another, from the same period, states that few data on hard outcomes in people who stop exist at all. Both are describing the same thin literature.

### Why would stopping increase cardiovascular risk?

The proposed routes are the return of weight and blood sugar, and the fluctuation itself. There is also a strong confound: people who stop early are disproportionately those who could not tolerate or afford the drug, or became unwell, and all of those independently predict worse outcomes.

### How fast does blood sugar go back?

HbA1c normalizes within 12 to 18 months of stopping, according to this review, meaning it returns to where it was before treatment.

### Is regaining weight a failure of willpower?

The review describes it as biology: reactivation of the hunger signaling that the drug suppressed, against a metabolic rate lowered by the weight loss itself. It is a physiological response to withdrawing an intervention.

### Is there a safe way to taper off?

No validated tapering strategy exists, which the review states directly. What does have randomized evidence is reducing rather than stopping, or handing over to another agent. Neither is a taper, and both beat stopping outright.

## References

1. Shah E, AlShiab R, Abdo A, et al. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2026. PMID: 41889156. https://pubmed.ncbi.nlm.nih.gov/41889156/

---

Cite as: GLP Watchdog, Nora Bissett, "Stopping as a Clinical Transition", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/stopping-as-a-clinical-transition

Canonical HTML page: https://glpwatchdog.org/research/stopping-as-a-clinical-transition

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
